Kardigan KARD
- Market cap
- $1.3B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| R&D | $18.8M | $35.8M | $45.1M | $56.4M |
| SG&A | $7.3M | $21.3M | $13.6M | $18.9M |
| −$26.1M | −$57.1M | −$58.7M | −$118.8M | |
| Pre-tax income | −$22.2M | −$57.4M | −$56.1M | −$116.2M |
| −$4.2M | $0 | $0 | $0 | |
| Net income | −$18M | −$57.4M | −$56.1M | −$116.2M |
| −$1.54 | −$4.64 | −$3.86 | −$4.61 | |
| 11.7M | 12.4M | 14.5M | 25.2M |
R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Kardigan's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KARDKardigan | $1.3B | n/m | n/a | n/m | n/m | n/m | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.6B | 15.0× | 57.5× | 1.7× | +31% | 11.1% | |
| HRMYHarmony Biosciences | $2.2B | 12.3× | 13.8× | 2.3× | +24% | 18.9% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| PBHPrestige Consumer Healthcare | $2.4B | 13.9× | 15.3× | 2.1× | −1% | 15.6% | |
| Peer median | $1.4B | 14.5× | 19.8× | 1.8× | +14% | 10.9% |
More on Kardigan
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .